Open label, multi-centre phase II study of raltitrexed ('Tomudex') in patients with inoperable squamous-cell carcinoma of head and neck

Annals of Oncology

Volumn 11, Issue 2, 2000, Pages 239-241

  Clarke, S J ^a,h   Zalcberg, J ^b   Olver, I ^c   Mitchell, P L R ^d   Rischin, D ^b   Dalley, D ^e   Green, M ^f   Davidson, Y Egan ^g  

^a SYDNEY CANCER CENTRE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

^d HEIDELBERG REPATRIATION HOSPITAL   (Australia)

^e ST VINCENT S HOSPITAL   (Australia)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

^g ASTRAZENECA   (United Kingdom)

^h ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Head and neck cancer; Phase II trial; Raltitrexed

Indexed keywords

RALTITREXED;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG RESPONSE; DRUG TOLERABILITY; DYSPNEA; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; LETHARGY; LIVER DYSFUNCTION; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; VOMITING;

EID: 0034111680     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008369629944     Document Type: Article

References (15)

1. Parkin D, Pisani P, Ferlay J. Global Cancer Statistics. CA Cancer J Clin 1999; 49: 33-64.
2. Vokes EE, Weichselbaum R, Lippman S, Hong W. Head and neck cancer. N Engl J Med 1993; 328: 184-94.
3. Cunningham D. Mature results from three large controlled studies with raltitrexed (Tomudex). Br J Cancer 1998; 77 (Suppl 2): 15-21.
4. Clarke SJ, Hanwell J, Planting A et al. Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. J Clin Oncol 1996; 14: 1495-503.
5. Hayward J, Rubens R, Carbone P et al. Assessment of response to therapy in advanced breast cancer. Br J Cancer 1977; 35: 292-8.
6. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
7. Maughan T, James R, Kerr D et al. Preliminary results of a multicentre randomised trial comparing three chemotherapy regimens (de Gramont, Lokich and Raltitrexed) in metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999; 18 (Abstr).
8. Zalcberg J. Overview of the tolerability of 'Tomudex' (raltitrexed): Collective clinical experience in advanced colorectal cancer. Anticancer Drugs 1997; 8 (Suppl 2): S17-22.
9. Bertino JR, Mosher MB, De Conti RC. Chemotherapy of cancer of the head and neck. Cancer 1973; 31: 1141-9.
10. Merlano M, Bacigalupo A, Benasso M et al. 5-Fluorouracil and high-dose folinic acid as second-line chemotherapy in head and neck cancer. Am J Clin Oncol 1990; 13: 1-3.
11. Kish JA, Ensley JF, Jacobs J et al. A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) and CACP + 5-FU bolus for recurrent and advanced squamous-cell carcinoma of the head and neck. Cancer 1985; 56: 2740-4.
12. Al Sarraf M. Head and neck cancer: Chemotherapy concepts. Semin Oncol 1988; 15: 70-85.
13. Forastiere AA, Metch B, Schuller DE et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study. J Clin Oncol 1992; 10: 1245-51.
14. The Liverpool Head and Neck Oncology Group. A phase III randomised trial of cisplatinum, methotrexate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Br J Cancer 1990; 61: 311-5.
15. Pivot X, Raymond E, Gedouin D et al. Phase II trial of MTA (LY231514) in advanced or recurrent squamous-cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 1999; 18 (Abstr).